Table 2.
Univariable and multivariable competing risks analyses defined hazard ratios for prostate cancer-specific mortality for each clinical characteristic.
| Clinical Characteristics | Univariable Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|---|
| No. Men | No. PC Deaths | HR (95% CI) | P-value | AHR (95% CI) | P-value | |
| PSA DT × PSA level at Salvage ADT | 54 | 27 | 0.63 (0.10, 3.84) | 0.62 | 0.13 (0.02, 1.03) | 0.05 |
| *PSA Doubling Time ≥ 6 months | ||||||
| PSA ≤ 12 ng/mL | 32 | 10 | 1.00 (referent) | 1.00 (referent) | ||
| PSA > 12 ng/mL | 5 | 3 | 4.26 (1.53, 11.86) | 0.006 | 8.84 (1.99, 39.27) | 0.004 |
| *PSA Doubling Time < 6 months | ||||||
| PSA ≤ 12 ng/mL | 8 | 6 | 1.00 (referent) | 1.00 (referent) | ||
| PSA > 12 ng/mL | 9 | 8 | 1.85 (0.57, 6.01) | 0.30 | 1.16 (0.38, 3.54) | 0.79 |
| Age, years | 54 | 27 | 0.95 (0.89, 1.004) | 0.07 | 0.98 (0.90, 1.07) | 0.65 |
| Interval to PSA failure, months | 54 | 27 | 0.96 (0.94, 0.99) | 0.003 | 0.97 (0.94, 1.003) | 0.08 |
| AJCC clinical tumor category | ||||||
| T1 | 20 | 8 | 1.00 (referent) | 1.00 (referent) | ||
| T2 | 34 | 19 | 1.71 (0.77, 3.80) | 0.19 | 1.33 (0.52, 3.37) | 0.55 |
| Highest Gleason Score | ||||||
| ≤ 6 | 11 | 2 | 1.00 (referent) | 1.00 (referent) | ||
| 7 | 30 | 17 | 4.03 (1.02, 15.89) | 0.046 | 3.19 (0.84, 12.12) | 0.09 |
| 8–10 | 13 | 8 | 5.43 (1.19, 24.64) | 0.03 | 4.39 (0.83, 23.34) | 0.08 |
| ADT × Comorbidity | 54 | 27 | 2.21 (0.15, 32.26) | 0.56 | 3.88 (0.24, 63.20) | 0.34 |
| No/minimal ACE-27 defined Comorbidity | ||||||
| RT | 31 | 19 | 1.00 (referent) | 1.00 (referent) | ||
| RT + ADT | 12 | 4 | 0.48 (0.16, 1.44) | 0.19 | 0.35 (0.06, 1.97) | 0.24 |
| Moderate/severe ACE-27 defined Comorbidity | ||||||
| RT | 8 | 3 | 1.00 (referent) | 1.00 (referent) | ||
| RT+ADT | 3 | 1 | 1.05 (0.09, 12.14) | 0.97 | 1.37 (0.19, 9.88) | 0.75 |
Abbreviations: ACE (Adult Comorbidity Evaluation-27), ADT (Androgen Deprivation Therapy), AHR (Adjusted Hazard Ratio), AJCC American Joint Commission on Cancer, CI (Confidence Interval), HR (Hazard Ratio), IQR (Interquartile Range), No. (Number), PC (Prostate Cancer), PSA (Prostate-Specific Antigen), RT (Radiation Therapy)
When PSA DT (per month increase) and level (ng/ml), both after log transformation, at time of salvage ADT were treated as continuous covariates and without an interaction term the respective AHR [95% CI]; p-value are 0.33 [0.13, 0.82]; 0.02 and 1.27 [0.69, 2.32]; 0.44, respectively.